ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.65
0.17%
US Tech 100
20,882.00
0.05%
S&P 500
6,039.31
-0.47%
US Dollar vs CAD
1.4434
0.23%
Bitcoin
104,881.34
1.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Vivoryon Therapeutics Nv (0R3M) Share Price

Vivoryon Therapeutics Nv

Vivoryon Therapeutics Nv (0R3M)

LSE
4.71
0.00
(0.00%)
Closed January 30 10:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
4.71
Bid
0.00
Ask
0.00
Volume
0.00
0.00 Day's Range 0.00
4.71 52 Week Range 4.71
Market Cap
-
Previous Close
4.71
Open
-
Last Trade
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
4,116
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeutics Nv

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeutics Nv is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R3M. The last closing price for Vivoryon Therapeutics Nv was 4.71 €. Over the last year, Vivoryon Therapeutics Nv shares have traded in a share price range of 4.71 € to 4.71 €.

Vivoryon Therapeutics Nv currently has 0 shares outstanding.

Ask ADVFN Intelligence (AI)

0R3M Latest News

More News

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

December 09 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

December 04 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

October 26 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

October 11 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

October 01 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

September 12 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

July 18 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

July 09 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1004.714.714.715374.71DE
4004.714.714.716994.71DE
12004.714.714.7141164.71DE
26004.714.714.7143684.71DE
52004.714.714.71122134.71DE
156004.714.714.7159984.71DE
260004.714.714.7142974.71DE

0R3M - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeutics Nv share price?
The current share price of Vivoryon Therapeutics Nv is 4.71 €
What is the 1 year trading range for Vivoryon Therapeutics Nv share price?
Vivoryon Therapeutics Nv has traded in the range of 4.71 € to 4.71 € during the past year
What is the reporting currency for Vivoryon Therapeutics Nv?
Vivoryon Therapeutics Nv reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeutics Nv?
The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeutics Nv?
The latest annual profit of Vivoryon Therapeutics Nv is EUR -28.34M
What is the registered address of Vivoryon Therapeutics Nv?
The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeutics Nv website address?
The website address for Vivoryon Therapeutics Nv is www.vivoryon.com
Which industry sector does Vivoryon Therapeutics Nv operate in?
Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
0A2IH World Group Ltd
US$ 0.00
(0.00%)
0
0A2DCrh Plc
US$ 0.00
(0.00%)
0
0A2BBanco Bilbao Vizcaya Argentaria Sa
US$ 0.00
(0.00%)
0
0A22Anheuser Busch Inbev Nv
US$ 0.00
(0.00%)
0
0A1UUber Technologies Inc
US$ 67.30
(0.00%)
466
0A2IH World Group Ltd
US$ 0.00
(0.00%)
0
0A2DCrh Plc
US$ 0.00
(0.00%)
0
0A2BBanco Bilbao Vizcaya Argentaria Sa
US$ 0.00
(0.00%)
0
0A22Anheuser Busch Inbev Nv
US$ 0.00
(0.00%)
0
0A1UUber Technologies Inc
US$ 67.30
(0.00%)
466
0R0XTesla Inc
US$ 393.90
(0.00%)
12.95k
0K8DNokia Oyj
US$ 6.24
(0.00%)
6.36k
0QYPMicrosoft Corp
US$ 444.50
(0.00%)
3.68k
0R24Intel Corp
US$ 19.89
(0.00%)
2.1k
0QZIMeta Platforms Inc
US$ 671.00
(0.00%)
1.18k

Discussion

View Full Feed
pegs1 pegs1 4 minutes ago
Test 🕵️
Thanks for the info!
CRTG
lovethatgreen lovethatgreen 11 minutes ago
Actually Marshall says a partner o another company he co founded has recieved a p1 project from a major defense contractor and will move to a phase 2 in Jan. He talks about the venture arm funding but its n o t clear who gets what exactly. The partner or moni or shieldcom or all 3
At the ve
MONI
Killmaril Killmaril 15 minutes ago
Manipulation here.. It´s done. Trumpet don´t like China. Ai manipulation with price... And many other stock...It sad..
TANH
jeunke22 jeunke22 19 minutes ago
https://www.linkedin.com/posts/cesarconda_pentagon-nationalsecurity-foreignpolicy-activity-7290508326080040960-U9h3?utm_source=share&utm_medium=member_android
NB
Plato_ Plato_ 20 minutes ago
Greetings, iamadog! You make great points. Thank you for them. I would like to expand on longevity and no dilution. VeeMost was founded in 2002 according to its https://veemost.com/about-veemost/ website . So, its longevity to date is about 23 years. VeeMost has been a public company for 2 years.
GDVM
gdl gdl 35 minutes ago
Middle of a despot's total control of this country and you only see profits. Like a pandemic declared and everyone ignored it. NO ONE can ever argue the facts on Trump, can they. they might approve or think it benefits them BUT not that he is a MONSTER.

Trump has 2 years to fix the
SPY
rbtree rbtree 40 minutes ago
Ummm, hate to break it to ya, but that is old news from over a year ago...

Meanwhile, this pig bounces between .000001 and .0001... does it even have a bid anymore?
KEGS
jeunke22 jeunke22 44 minutes ago
Just to prove that we need more low latency, bandwidth and speed …. This is the answer to a simple question:
“ Sorry, DeepSeek search service is busy. Please disable search or try again later.”
LWLG
gdl gdl 48 minutes ago
Not only has all 3 branches of government greedily abandoned their pledge they also have lost their souls. I warned, no insisted this was happening. it spells the end of our Republic and end of the stock market. no not for a year or 5 but for decades. The godlike Trump flexes and extends his muscl
RuudSaltis RuudSaltis 53 minutes ago
That’s why he needs only 6 months….! He has a razer sharp plan. It’s amazing how he communicates also one on one with shareholders…
LWLG
wagner wagner 53 minutes ago
I would bet no smart money in before the Exim in on stage... 
NB
Truenorth2016 Truenorth2016 56 minutes ago
Just a Reminder to you and anyone lurking, we just saw the Quantum Computing Healthcare stock RG*ti run from .66 cents to $21.00 in a few months. What people need to understand is GCAN already told us they are being approach by companies for a Quantum Computing /AI merger "BUT" I the CEO never told
GCAN
ramfan60 ramfan60 59 minutes ago
What's wrong with the wingnut? You must be happy with the wonderful job our FDA and NIH have done regulating our food and nutrition over the past 50 years. RFK is passionate about Making America Healthy Again......I'm all for it and he can't get confirmed fast enough as far as I'm concerned.
AMRN
ron_66271 ron_66271 1 hour ago
Thank for Supporting My Argument.

JPM didn’t have the money to cover Lehman’s ‘Market to Market’ of $17 Billion on September 14th.

Need more?

“BlackRock?”
Why…


All Classes are in the Money.



Ron
JPM
Zorax Zorax 1 hour ago
He's going to sell them shitface bibles.
Doc logic Doc logic 1 hour ago
exwannabe,

Simply put: Crossover to an active substance instead of placebo required that the active substance being utilized in the crossover be measured against a comparable group being treated with anything other than a known active substance. Comparators had to be changed when SO
NWBO
ron_66271 ron_66271 1 hour ago
CTS are in the Same Camp as Preferred Shares.

Securitized by Derivative Contracts.

You didn’t understand the Derivative Market Meltdown of 2008.

Lehman’s wasn’t the problem.
JPM was.



Ron
JPM
littlejohn littlejohn 1 hour ago
Traders who played other big names for

Wednesday could start back in

here on the cheapies...

META and MSFT make a lot of money...

And can spend on Ai - R and D...

Seems a good money flow watch...

so we watch..
MSFT
hbhmb hbhmb 1 hour ago
You are right. To much going on behind the scenes. Also the volume ( or lack of such) is causing the swings allowing flippers to flip
Hopefully the next quarters financials will continue improving and with the new web site am hoping we start moving nicely.
AIAD
Wrangler1 Wrangler1 1 hour ago
Wonder why he's deleting posts? Probably  because he realizes he is wrong once again. What an absolute joke. 
WDLF
Golfnut3 Golfnut3 1 hour ago
Thanks for the input...
ALYI
littlejohn littlejohn 2 hours ago
Fine idea, put sellers on 28 turned bullish

on Wednesday with big volume...

https://www.barchart.com/stocks/quotes/SMCI/options?expiration=2025-01-31-w&moneyness=20

those are willing share buyers at 28

if they get exercised with a close on
SMCI
trader53 trader53 2 hours ago
DPLS 0.0004 - Short Squeeze Soon!


I'll Alert you of stocks to Buy,
before the Run happens !

https://investorshub.advfn.com/uicon/155361.png?cb=636360310707230000
________________________________________________


https://
DPLS MFI

Your Recent History

LSE
0R3M
Vivoryon Therapeutics Nv
BIT
F31902
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads